Ace-232 Tablets
mCRPC (Metastatic Castration-resistant Prostate Cancer)
Acerand Therapeutics (Hong Kong) LimitedPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
229 Active assets in the mCRPC (Metastatic Castration-resistant Prostate Cancer) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Darolutamide Bayer | Phase 4 | BBB |
Enzalutamide Prostate Cancer Clinical Trials Consortium | Phase 4 | BBB |
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Ding-Wei Ye | Phase 4 | BBB |
Darolutamide Bayer | Phase 3 | BB |
Bms-907351 Rana McKay, MD | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Ace-232 Tablets is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →